In another experimental study [64], combination immunotherapy induced the regression of large established tumors in three mouse transplantation models when four components were administered: an antibody specific to a surface tumor antigen, a stabilized recombinant interleukin-2, an antibody blocking the PD-1 receptor, and a powerful vaccine activating CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.